Evcazolin Aqua nasal spray 1 mg/g. 10 g.


Manufacturer: Ukraine

Symptomatic treatment of nasal congestion in colds, hay fever, allergic rhinitis, sinusitis. To facilitate the outflow of secretions in diseases of the paranasal sinuses. Auxiliary therapy for otitis media (to reduce swelling of the nasal mucosa). For diagnostic interventions (rhinoscopy).



Evcazolin Aqua Composition
active substance: хylometazoline;

1 g of spray contains xylometazoline hydrochloride in terms of 100% substance 1 mg;

excipients: benzalkonium chloride, eucalyptus oil; disodium edetate; propylene glycol; polyethylene glycol 1500; povidone, hypromellose; polysorbate 20; sodium phosphate, dodecahydrate; potassium dihydrogen phosphate; purified water.

Evcazolin Aqua Dosage form
Nasal spray.

Basic physical and chemical properties: when leaving the bottle through a dosing pump with a nasal spray, the drug is sprayed in the form of an aerosol jet, which has a specific odor and is dispersed in the air of liquid particles.

Pharmacological group
Means used for diseases of the nasal cavity. Decongestants and other topical preparations for diseases of the nasal cavity. Sympathomimetics, simple drugs. ATX code R01A A07.

Pharmacological properties


Xylometazoline is a sympathomimetic agent that acts on α-adrenergic receptors.

Xylometazoline, when administered nasally, causes a narrowing of the blood vessels of the nasal mucosa and adjacent areas of the nasopharynx, thus eliminating edema and hyperemia of the nasal and nasopharyngeal mucosa, and also reduces the associated increased mucus production and facilitates the removal of blocked nasal secretions, which leads to nasal clearance. passages and relief of nasal breathing.

The effect of the drug begins within 2 minutes after application and lasts up to 12 hours (for example, throughout the night).

The drug is well tolerated by patients with sensitive mucous membranes and does not reduce mucociliary function. Research results have shown that xylometazoline reduces the infectious activity of human rhinovirus, associated with the common cold.

Evcazolin Aqua Pharmacokinetics.

When applied topically, xylometazoline is practically not absorbed, the concentration of xylometazoline in the blood plasma is so low that it is practically not detected (the concentration in the blood plasma is close to the definition limit).

Xylometazoline is not mutagenic. Also, in animal studies, no teratogenic effects of xylometazoline were detected.

Symptomatic treatment of nasal congestion with colds, hay fever, other allergic rhinitis, sinusitis.

To facilitate the outflow of secretions in diseases of the paranasal sinuses.

Adjunctive therapy for otitis media (to eliminate swelling of the nasal mucosa).

To facilitate rhinoscopy.

Hypersensitivity to xylometazoline or to any other component of the drug, acute coronary diseases, coronary asthma, hyperthyroidism, angle-closure glaucoma, transphenoidal hypophysectomy and surgery with exposure of the meninges in history, dry rhinitis (rhinitis sicca) or atrophic rhinitis. Concomitant treatment with MAO inhibitors and within 2 weeks after stopping their use.